tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
BIIB is currently covered by 19 analysts with an average price target of $219.19. This is a potential upside of $39.39 (9.52%) from yesterday's end of day stock price of $200.14.
Biogen's activity chart (see below) currently has 1,180 price targets and 920 ratings on display. The stock rating distribution of BIIB is 61.82% HOLD, 36.36% BUY and 1.82% SELL.
Analysts average stock forecasts to be materialized ratio is 60.07% with an average time for these price targets to be met of 209.7 days.
Highest price target for BIIB is $275, Lowest price target is $150, average price target is $219.19.
Most recent stock forecast was given by SRIKRIPA DEVARAKONDA from TRUIST on 13-Jul-2026. First documented stock forecast 09-Sep-2010.
Biogen is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.
Biogen offers a diverse portfolio of therapies targeting various neurological conditions.
For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.
Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.
In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.
Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.
Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.
Currently out of the existing stock ratings of BIIB, 34 are a HOLD (61.82%), 20 are a BUY (36.36%), 1 are a SELL (1.82%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 21-Jul-2025
$235
$32.81 (16.23%)
$189
15 days ago
(13-Jul-2026)
5/8 (62.5%)
$25.97 (12.42%)
164
Hold Since 13-Feb-2025
$222
$19.81 (9.80%)
$224
20 days ago
(08-Jul-2026)
38/66 (57.58%)
$21.64 (10.80%)
321
Buy Since 04-Mar-2022
$242
$39.81 (19.69%)
$227
21 days ago
(07-Jul-2026)
48/83 (57.83%)
$36.3 (17.65%)
148
Buy Since 29-Jun-2026
$256
$53.81 (26.61%)
$255
29 days ago
(29-Jun-2026)
7/37 (18.92%)
$39.37 (18.17%)
256
Buy Since 28-Sep-2022
$221
$4.97 (2.30%)
$177
1 months 13 days ago
(15-Jun-2026)
24/40 (60%)
$22.36 (11.26%)
155
What is BIIB (Biogen) average time for price targets to be met?
Which analyst has the current highest performing score on BIIB (Biogen) with a proven track record?
Which analyst has the most public recommendations on BIIB (Biogen)?
Which analyst is the currently most bullish on BIIB (Biogen)?
Which analyst is the currently most reserved on BIIB (Biogen)?
